Rapt, 3M, D.R. Horton - podcast episode cover

Rapt, 3M, D.R. Horton

Jan 20, 20264 min
--:--
--:--
Download Metacast podcast app
Listen to this episode in Metacast mobile app
Don't just listen to podcasts. Learn from them with transcripts, summaries, and chapters for every episode. Skim, search, and bookmark insights. Learn more

Episode description

On this episode of Stock Movers:
- GSK (GSK) agreed to buy Rapt Therapeutics (RAPT), a US-based biotech developing treatments for patients with inflammatory and immunologic diseases, in a deal valued at $2.2 billion. The UK drug company will pay $58 a share, equivalent to an equity value of $2.2 billion, according to a statement Tuesday. The price represents a premium of 65% compared with Rapt Therapeutics’ closing price of $35.10 on Monday.
- 3M (MMM) expects profit and sales to expand this year, signaling the company’s push to prioritize higher-growth markets and accelerate the introduction of new products will continue to lift its results.Adjusted earnings will be $8.50 to $8.70 a share in 2026, the maker of Post-it notes, roofing granules and electronics materials said Tuesday in a statement that also revealed better-than-expected quarterly results. Analysts had expected $8.64 on average, according to the average of estimates compiled by Bloomberg. Adjusted sales will climb about 4%, the company said.
- Homebuilder D.R. Horton (DHI) missed analysts’ estimates for quarterly home orders even as mortgage rates slid. The company reported 18,300 signed contracts for the three months through December, up 3% from a year earlier, according to a statement Tuesday. Analysts were expecting 18,653, the average in a survey compiled by Bloomberg.

See omnystudio.com/listener for privacy information.

Transcript

Speaker 1

Bloomberg Audio Studios, podcasts, radio News, The.

Speaker 2

Stock Movers Report, your roundup of companies making moves in the stock market. Harnessing the power of Bloomberg Data.

Speaker 1

Let's take a look at some stocks on the move today. I'm Nathan Hager, joined by Bloomberg's Dan Curtis on what's already been a pretty busy earnings morning. But before we get to that, Dan, we're starting a holiday shortened training week, So I guess we could call this merger Monday observed in the pharma space.

Speaker 3

Good morning, Good morning. I like that. Yeah, so everyone had a bit of a holiday yesterday, but we still got some deals out, particularly a deal for Wrapped Therapeutics tick our raapt GSK has agreed to buy the company at eight fifty eight dollars a share in a deal

valued at two point two billion dollars. That sent the stock up to fifty seven to fifty so just short of that fifty eight dollars share target, sixty three percent increase from where it closed on Friday, So a good day for the investors in that the acquisition includes a drug that's being tested to help protect against food allergens with an injection every eight to twelve weeks instead of

the typical two to four week cycles needed. Right now, GSK shares about flat, and again, that's not too bad for a morning that's seeing a lot of red in the equity markets. This deal will give GSK pipeline to bolster revenues after the patent on its top selling HIV drug expires. And Jeffrey is calling this deal quote unquote sensible, which is a nice British term. It sounds like, yeah, doesn't it.

Speaker 1

Let's get to some of the earnings. We've heard some from some big names already, including three M.

Speaker 3

That's right. So this is the company that makes post its and it's posted a six billion dollar revenue, just slightly lighter than estimates, but earnings came in a dollar eighty three a share. That was a beat. It also issued guidance for the year, so it's seeing about eight dollars and fifty to eight dollars and seventy cents a

share in earnings for twenty twenty six. That might touch software than analysts hoped for, as the estimates were towards the higher end of that range eight dollars and sixty four cents a share. Those shares are down almost two percent in pre market. Company is focusing on streamlining operations and bringing new products to the market faster, and it's also been benefiting from data center construction. Boom VIAAC is about three percent of three MS revenue coming from that space.

So you know, the shares were down a little bit before the earnings and they're about at the same level as they were ahead, so a little bit of a grain of salt, but not not a huge sell off like we're seeing some other names.

Speaker 1

Speaking of construction, not data centers, but actual houses. We also heard from Dr Horton this morning.

Speaker 3

That's right. It is a home builder and that's that's an area that Trump's really been looking at with the affordability push, and Dr Horton shares up about six tenths of percent. Those were down almost two percent before earnings, so that's that's actually a decent boost from where they were before the earnings came out. The home builder reported six point nine billion dollars in revenue, with adjusted earnings per share of two dollars and three cents. That's both

were beats. Orders for new homes were lighter than estimates, but that was offset by the company closing a higher number of new builds. D R Horton sticking to its full year guidance, it sees sales up to thirty five billion dollars for the year.

Speaker 1

All right, just thirty seconds left. How's Netflix doing before they report earnings after the bell.

Speaker 3

That's right, Netflix, it's another green spot. Up one percent. They're reporting after the bell. We have stranger things that came out in the recent quarter, so we'll see some dollar figures behind that. And we also have the the bidding war over Warner Brothers going on. Worth noting that there's a deadline tomorrow for the counterbids from Paramount Sky. Basically all the tender offers have to be accepted by then, so we should have some deal news on top of that.

So Netflix up just under one percent in the pre market.

Speaker 2

This stock movers report from Bloomberg Radio. Check back with us throughout the day for the latest roundup of companies making news on Wall Street and for the latest market moving headlines. Listen to bloom Radio Live, catch us on YouTube, Bloomberg dot com, and on Applecarplay and Android Auto with the Bloomberg Business app.

Transcript source: Provided by creator in RSS feed: download file
For the best experience, listen in Metacast app for iOS or Android